The stock of Juno Therapeutics Inc (NASDAQ:JUNO) is a huge mover today! About 1.07 million shares traded hands. Juno Therapeutics Inc (NASDAQ:JUNO) has declined 40.66% since April 4, 2016 and is downtrending. It has underperformed by 41.75% the S&P500.
The move comes after 8 months positive chart setup for the $2.39B company. It was reported on Nov, 4 by Barchart.com. We have $31.46 PT which if reached, will make NASDAQ:JUNO worth $812.60 million more.
Analysts await Juno Therapeutics Inc (NASDAQ:JUNO) to report earnings on November, 8. They expect $-0.64 earnings per share, down 18.52% or $0.10 from last year’s $-0.54 per share. After $-0.65 actual earnings per share reported by Juno Therapeutics Inc for the previous quarter, Wall Street now forecasts -1.54% EPS growth.
Juno Therapeutics Inc (NASDAQ:JUNO) Ratings Coverage
Out of 9 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Juno Therapeutics Inc has been the topic of 18 analyst reports since July 22, 2015 according to StockzIntelligence Inc. Citigroup initiated the stock with “Buy” rating in Thursday, February 25 report. As per Tuesday, December 15, the company rating was upgraded by Standpoint Research. Maxim Group maintained it with “Buy” rating and $50 target price in Friday, August 5 report. The rating was initiated by Suntrust Robinson on Friday, January 29 with “Buy”. Raymond James initiated the stock with “Outperform” rating in Thursday, June 2 report. The rating was maintained by FBR Capital on Friday, July 8 with “Outperform”. The firm earned “Outperform” rating on Wednesday, July 22 by Northland Capital. On Wednesday, November 18 the stock rating was initiated by Goldman Sachs with “Neutral”. The firm has “Outperform” rating given on Tuesday, August 18 by FBR Capital. The company was initiated on Wednesday, July 6 by Barclays Capital.
According to Zacks Investment Research, “Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.34 in 2016 Q2. Its up 0.26, from 1.08 in 2016Q1. The ratio improved, as 25 funds sold all Juno Therapeutics Inc shares owned while 36 reduced positions. 23 funds bought stakes while 59 increased positions. They now own 44.56 million shares or 5.68% more from 42.17 million shares in 2016Q1.
Moreover, Royal Savings Bank Of Canada has 0% invested in Juno Therapeutics Inc (NASDAQ:JUNO) for 5,942 shares. Capital Fund Management Sa accumulated 23,213 shares or 0.01% of the stock. Pictet Asset Mngmt holds 0.03% or 180,438 shares in its portfolio. Wells Fargo & Mn last reported 14,577 shares in the company. Bb Biotech Ag reported 1.31M shares or 1.98% of all its holdings. 1832 Asset L P owns 95,200 shares or 0.01% of their US portfolio. Metropolitan Life Ins Ny has 0% invested in the company for 4,441 shares. Panagora Asset Mngmt owns 2,710 shares or 0% of their US portfolio. Savings Bank Of New York Mellon has 0% invested in the company for 259,047 shares. Perceptive Advisors Llc last reported 1,113 shares in the company. The New York-based Tocqueville Asset Ltd Partnership has invested 0.02% in Juno Therapeutics Inc (NASDAQ:JUNO). Capital Ww Investors owns 3.64M shares or 0.04% of their US portfolio. Mariner Investment Group Ltd Liability Corp has 0.23% invested in the company for 17,700 shares. State Board Of Administration Of Florida Retirement last reported 37,223 shares in the company. First Allied Advisory Service holds 0.05% or 21,152 shares in its portfolio.
More notable recent Juno Therapeutics Inc (NASDAQ:JUNO) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics” on November 03, 2016, also Benzinga.com with their article: “BTIG Is No Longer Selling Juno Therapeutics Stock” published on November 04, 2016, Zacks.com published: “Will Juno Therapeutics (JUNO) Disappoint in Q3 Earnings?” on November 03, 2016. More interesting news about Juno Therapeutics Inc (NASDAQ:JUNO) were released by: Fool.com and their article: “Better Buy: Juno Therapeutics vs. Inovio Pharmaceuticals” published on October 28, 2016 as well as Businesswire.com‘s news article titled: “Juno Therapeutics to Report Third Quarter 2016 Financial Results on Wednesday …” with publication date: November 02, 2016.
JUNO Company Profile
Juno Therapeutics, Inc. (Juno), incorporated on August 5, 2013, is a biopharmaceutical firm focused on re-engaging the bodyâ€™s immune system to revolutionize the treatment of cancer. The Firm is developing cell cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. The Company’s CAR and TCR technologies alter T cells ex vivo, or outside the body. In addition, the Company holds license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.